GENOMTEC S.A. ZY -10 Market Cap ($9.11 Million)
Market Cap & Net Worth: GENOMTEC S.A. ZY -10 (4VI)
GENOMTEC S.A. ZY -10 market cap. GENOMTEC S.A. ZY -10 (F:4VI) has a market capitalization of $9.11 Million (€7.79 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #27174 globally and #2323 in its home market, demonstrating a -8.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GENOMTEC S.A. ZY -10's stock price €0.52 by its total outstanding shares 15064634 (15.06 Million).
GENOMTEC S.A. ZY -10 Market Cap History (2021–2026)
GENOMTEC S.A. ZY -10 market cap history from 2021 to 2026. Data shows change from $34.13 Million to $9.11 Million (-25.45% CAGR). Check latest GENOMTEC S.A. ZY -10 stock price today for real-time trading data and today's change.
GENOMTEC S.A. ZY -10 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GENOMTEC S.A. ZY -10's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 4VI by Market Capitalization
Companies near GENOMTEC S.A. ZY -10 in the global market cap rankings as of November 4, 2026.
Key companies related to GENOMTEC S.A. ZY -10 by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #110 globally with a market cap of $191.55 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #204 globally with a market cap of $117.68 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #227 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #240 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #110 | Abbott Laboratories | NYSE:ABT | $191.55 Billion | $110.16 |
| #204 | Stryker Corporation | NYSE:SYK | $117.68 Billion | $306.81 |
| #227 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $99.29 |
| #240 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of GENOMTEC S.A. ZY -10 (2021–2026)
Market capitalization of GENOMTEC S.A. ZY -10 from 2021 to today. Between 2021 and today, GENOMTEC S.A. ZY -10's market cap moved from $34.13 Million to $ 9.11 Million, with a yearly change of -25.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €9.11 Million | -36.17% |
| 2025 | €14.27 Million | -46.00% |
| 2024 | €26.42 Million | -33.63% |
| 2023 | €39.80 Million | +38.48% |
| 2022 | €28.74 Million | -15.79% |
| 2021 | €34.13 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of GENOMTEC S.A. ZY -10 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.11 Million USD |
| MoneyControl | $9.11 Million USD |
| MarketWatch | $9.11 Million USD |
| marketcap.company | $9.11 Million USD |
| Reuters | $9.11 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GENOMTEC S.A. ZY -10
Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company's flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysi… Read more